Literature DB >> 32839832

Intraoperative blood loss as an independent prognostic factor for curative resection after neoadjuvant chemotherapy for gastric cancer: a single-center retrospective cohort study.

Masato Hayashi1, Takaki Yoshikawa2, Masahiro Yura1, Sho Otsuki1, Yukinori Yamagata1, Shinji Morita1, Hitoshi Katai1, Toshirou Nishida1.   

Abstract

PURPOSE: Surgery-induced factors such as postoperative infectious complications (PICs) and intraoperative blood loss (IBL) have a negative impact on the survival of patients undergoing surgery for gastric cancer. A recent study showed that neoadjuvant chemotherapy (NAC) could reduce the negative impact of PICs; hence, we conducted the present study to investigate if NAC can also reduce the negative prognostic impact of IBL.
METHODS: We reviewed 115 gastric cancer patients treated with NAC and radical gastrectomy. The cut-off for IBL predicting the long-term survival was assessed by a receiver operating characteristic curve. The Cox proportional hazard model was used to evaluate the association between patient characteristics including IBL, overall survival, and disease-free survival.
RESULTS: The cut-off for IBL was set at 990 ml. Twenty-six patients had excessive IBL exceeding 990 ml (22.6%) and PICs developed in 33 patients (28.7%). The body mass index, IBL, ypT, and ypN were significant independent prognostic predictors, but PICs were not.
CONCLUSION: NAC did not decrease the risk induced by excessive IBL. The prophylactic effect of NAC on surgery-induced risk was inconsistent.

Entities:  

Keywords:  Blood loss; Gastric cancer; Neoadjuvant chemotherapy

Mesh:

Year:  2020        PMID: 32839832     DOI: 10.1007/s00595-020-02114-3

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  23 in total

1.  Impact of intraoperative blood loss on survival after curative resection for gastric cancer.

Authors:  Yue-Xiang Liang; Han-Han Guo; Jing-Yu Deng; Bao-Gui Wang; Xue-Wei Ding; Xiao-Na Wang; Li Zhang; Han Liang
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

2.  Prophylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications.

Authors:  Kojiro Eto; Naoki Hiki; Koshi Kumagai; Yoshiaki Shoji; Yasuo Tsuda; Yosuke Kano; Itaru Yasufuku; Yasuhiro Okumura; Masahiro Tsujiura; Satoshi Ida; Souya Nunobe; Manabu Ohashi; Takeshi Sano; Toshiharu Yamaguchi
Journal:  Gastric Cancer       Date:  2017-11-29       Impact factor: 7.370

3.  Phase II study of docetaxel and S-1 (DS) as neoadjuvant chemotherapy for clinical stage III resectable gastric cancer.

Authors:  Eiji Oki; Yasunori Emi; Tetsuya Kusumoto; Yoshihisa Sakaguchi; Manabu Yamamoto; Noriaki Sadanaga; Mototsugu Shimokawa; Takeharu Yamanaka; Hiroshi Saeki; Masaru Morita; Ikuo Takahashi; Naoki Hirabayashi; Kenji Sakai; Hiroyuki Orita; Shinichi Aishima; Yoshihiro Kakeji; Kazuya Yamaguchi; Kazuhiro Yoshida; Hideo Baba; Yoshihiko Maehara
Journal:  Ann Surg Oncol       Date:  2014-03-07       Impact factor: 5.344

Review 4.  Gastric cancer.

Authors:  Eric Van Cutsem; Xavier Sagaert; Baki Topal; Karin Haustermans; Hans Prenen
Journal:  Lancet       Date:  2016-05-05       Impact factor: 79.321

5.  Preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer.

Authors:  Takashi Kosaka; Hirotoshi Akiyama; Hirochika Makino; Ryo Takagawa; Jun Kimura; Hidetaka Ono; Chikara Kunisaki; Itaru Endo
Journal:  Cancer Chemother Pharmacol       Date:  2013-11-20       Impact factor: 3.333

6.  Adverse Effects of Intraoperative Blood Loss on Long-Term Outcomes after Curative Gastrectomy of Patients with Stage II/III Gastric Cancer.

Authors:  Akira Mizuno; Mitsuro Kanda; Daisuke Kobayashi; Chie Tanaka; Naoki Iwata; Suguru Yamada; Tsutomu Fujii; Goro Nakayama; Hiroyuki Sugimoto; Masahiko Koike; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Dig Surg       Date:  2016-01-09       Impact factor: 2.588

7.  Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer.

Authors:  T Yoshikawa; M Sasako; S Yamamoto; T Sano; H Imamura; K Fujitani; H Oshita; S Ito; Y Kawashima; N Fukushima
Journal:  Br J Surg       Date:  2009-09       Impact factor: 6.939

8.  Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer.

Authors:  Akira Tsuburaya; Naoki Nagata; Haruhiko Cho; Naoki Hirabayashi; Michiya Kobayashi; Hiroshi Kojima; Yasuhiro Munakata; Ryoji Fukushima; Yoichi Kameda; Tadakazu Shimoda; Koji Oba; Junichi Sakamoto
Journal:  Cancer Chemother Pharmacol       Date:  2013-03-05       Impact factor: 3.333

9.  Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis.

Authors:  A Tsuburaya; J Mizusawa; Y Tanaka; N Fukushima; A Nashimoto; M Sasako
Journal:  Br J Surg       Date:  2014-03-25       Impact factor: 6.939

10.  Intraoperative blood loss is a critical risk factor for peritoneal recurrence after curative resection of advanced gastric cancer.

Authors:  Takao Kamei; Joji Kitayama; Hiroharu Yamashita; Hirokazu Nagawa
Journal:  World J Surg       Date:  2009-06       Impact factor: 3.352

View more
  2 in total

1.  Does Intraoperative Blood Loss Affect the Short-Term Outcomes and Prognosis of Gastric Cancer Patients After Gastrectomy? A Meta-Analysis.

Authors:  Ze-Lin Wen; Da-Chun Xiao; Xiong Zhou
Journal:  Front Surg       Date:  2022-06-14

Review 2.  The Impact of Perioperative Events on Cancer Recurrence and Metastasis in Patients after Radical Gastrectomy: A Review.

Authors:  Xing Zhi; Xiaohong Kuang; Jian Li
Journal:  Cancers (Basel)       Date:  2022-07-19       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.